title: Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses.
abstract: BACKGROUND
  Enterovirus 71 (EV71) is major cause of hand, foot and mouth disease. Large epidemics of EV71 infection have been recently reported in the Asian-Pacific region. Currently, no vaccine is available to prevent EV71 infection.
  
  
  RESULTS
  The peptide (VP4N20) consisting of the first 20 amino acids at the N-terminal of VP4 of EV71 genotype C4 were fused to hepatitis B core (HBcAg) protein. Expression of fusion proteins in E. coli resulted in the formation of chimeric virus-like particles (VLPs). Mice immunized with the chimeric VLPs elicited anti-VP4N20 antibody response. In vitro microneutralization experiments showed that anti-chimeric VLPs sera were able to neutralize not only EV71 of genotype C4 but also EV71 of genotype A. Neonatal mice model confirmed the neutralizing ability of anti-chimeric VLPs sera. Eiptope mapping led to the identification of a "core sequence" responsible for antibody recognition within the peptide.
  
  
  CONCLUSIONS
  Immunization of chimeric VLPs is able to elicit antibodies displaying a broad neutralizing activity against different genotypes of EV71 in vitro. The "core sequence" of EV71-VP4 is highly conserved across EV71 genotypes. The chimeric VLPs have a great potential to be a novel vaccine candidate with a broad cross-protection against different EV71 genotypes.
authors: Miao
authors: M
authors: Zhao
authors: Yu
authors: Y
authors: Bai
authors: Wei
authors: W
authors: Liu
authors: Xiangqian
authors: X
authors: Xiao
authors: Yuming
authors: Y
authors: Huang
authors: Shan
authors: S
authors: Cen
authors: Paul K S
authors: PK
authors: Chan
authors: College of Life Science and Bioengineering, Beijing University of Technology, 100, Pingleyuan, Chaoyang District, Beijing 100124, PR China. sunxinbh@126.com.
authors: Xin
authors: X
authors: Sun
authors: Wang
authors: W
authors: Sheng
authors: Yi
authors: Y
authors: Zeng
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D056738:Cross Protection; D003429:Cross Reactions; D004195:Disease Models, Animal; D029821:Enterovirus A, Human / Q000235:genetics / Q000276:immunology*; D005260:Female; D006232:Hand, Foot and Mouth Disease / Q000276:immunology / Q000517:prevention & control*; D006512:Hepatitis B Core Antigens / Q000235:genetics / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D058425:Vaccines, Virus-Like Particle / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D006512:Hepatitis B Core Antigens; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; D058425:Vaccines, Virus-Like Particle; D014764:Viral Proteins; D014765:Viral Vaccines